2h
Investor's Business Daily on MSNBehind Hims Stock's Roller-Coaster Ride As Weight-Loss Drugs Battle Heats UpHims & Hers Health put out a jaw dropping commercial. Now, Hims stock is just dropping, as its semaglutide business faces a ...
New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...
People with a high body weight living in England can now access subsidized weight-loss drugs to treat their obesity. This ...
It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...
Medicare spending on some diabetes drugs, including popular treatments such as Ozempic, surged nearly five-fold to $35.8 ...
The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.
2don MSN
Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, ...
People who have depended on off-brand versions of Wegovy and Ozempic will likely have to pay more now that a nationwide ...
Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results